Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27698867 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2GABRR1PLA2G2APLA2G5GSR | |
| SCHEMBL3188611 | 0.88 | GABRR1 (0.46) | SMN1; SMN2GABRR1PLA2G2APLA2G5NPSR1 | |
| SCHEMBL2232656 | 0.88 | GABRR1 (0.46) | SMN1; SMN2GABRR1PLA2G2APLA2G5NPSR1 | |
| SCHEMBL2232653 | 0.88 | GABRR1 (0.46) | SMN1; SMN2GABRR1PLA2G2APLA2G5NPSR1 | |
| SCHEMBL4622349 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2PLA2G2APLA2G5NPSR1 | |
| SCHEMBL11582357 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2PLA2G2APLA2G5 | |
| SCHEMBL3360269 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2PLA2G2APLA2G5NPSR1EPHX2 | |
| SCHEMBL30001304 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2PLA2G2APLA2G5NPSR1EPHX2 | |
| SCHEMBL11582359 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2PLA2G2APLA2G5 | |
| SCHEMBL31390813 | 0.81 | CA12 (0.44) | SMN1; SMN2PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1068224-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | Du Pont Pharmaceuticals Company (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999058162-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-11-18 | — | — | WO | claimed |
| EP-1337278-A2 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | Bristol-Myers Squibb Medical Imaging, Inc. (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1311302-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | Bristol-Myers Squibb Pharma Company (US) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002055111-A2 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | BRISTOL MYERS SQUIBB MEDICAL I (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2001097860-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS FOR USE IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| CN-1295578-A | Pharmaceuticals for imaging of angiogenic disorders | PONT PHARMACEUTICAL CO DU (US) | 2001-05-16 | — | — | CN | disclosed |
| EP-1068224-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | Du Pont Pharmaceuticals Company (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999058162-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-11-18 | — | — | WO | disclosed |